Trexquant Investment LP Purchases New Holdings in Becton Dickinson and Co (BDX)

Trexquant Investment LP purchased a new stake in Becton Dickinson and Co (NYSE:BDX) during the 3rd quarter, HoldingsChannel.com reports. The firm purchased 2,010 shares of the medical instruments supplier’s stock, valued at approximately $525,000.

A number of other institutional investors have also recently bought and sold shares of BDX. Fundsmith Equity Fund L.P. bought a new position in Becton Dickinson and in the second quarter valued at about $894,775,000. FMR LLC boosted its holdings in Becton Dickinson and by 13.7% in the second quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock valued at $4,069,559,000 after acquiring an additional 2,049,874 shares during the last quarter. Charles Schwab Investment Advisory Inc. bought a new position in Becton Dickinson and in the second quarter valued at about $291,167,000. Vontobel Asset Management Inc. boosted its holdings in Becton Dickinson and by 823.0% in the second quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock valued at $250,205,000 after acquiring an additional 904,097 shares during the last quarter. Finally, Cornerstone Wealth Management LLC boosted its holdings in Becton Dickinson and by 233.6% in the third quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock valued at $3,286,000 after acquiring an additional 453,623 shares during the last quarter. Institutional investors and hedge funds own 85.19% of the company’s stock.

Several equities analysts recently issued reports on BDX shares. KeyCorp raised their price target on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a report on Thursday, November 8th. Wells Fargo & Co raised their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup decreased their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Morgan Stanley raised their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Finally, UBS Group started coverage on Becton Dickinson and in a report on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 price target on the stock. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $254.20.

NYSE:BDX opened at $244.92 on Wednesday. Becton Dickinson and Co has a 1-year low of $209.91 and a 1-year high of $265.87. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $67.80 billion, a price-to-earnings ratio of 22.25, a P/E/G ratio of 1.75 and a beta of 1.21.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the Zacks’ consensus estimate of $2.93. The company had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. Becton Dickinson and’s revenue was up 39.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.40 earnings per share. Research analysts anticipate that Becton Dickinson and Co will post 12.1 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.26%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.25%.

In other news, CEO Vincent A. Forlenza sold 16,866 shares of the firm’s stock in a transaction dated Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total transaction of $4,007,530.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP James W. Borzi sold 5,887 shares of the firm’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $252.37, for a total value of $1,485,702.19. Following the sale, the executive vice president now directly owns 6,013 shares in the company, valued at approximately $1,517,500.81. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,795 shares of company stock worth $19,571,318. 1.00% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/05/trexquant-investment-lp-purchases-new-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply